Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index; 73 of the 169 sources its claims cite were checked for support.
Abstract
Endogenous Cushing syndrome (CS) is a rare disorder resulting from chronic exposure to excessive concentrations of cortisol. It is likely underdiagnosed because many clinical signs and symptoms are non-specific and overlap with those of common conditions. Furthermore, biochemical testing to diagnose CS can be complex and challenging, especially in milder cases. CS is characterized by excessive daily cortisol production, but it is also associated with a disrupted circadian rhythm of cortisol secretion. Traditional cortisol monitoring techniques rely on single-time-point measurements or a cumulation of measurements, which are unable to capture the complete daily rhythm of cortisol fluctuations. Currently, the utility of assessing individual patients' cortisol circadian rhythm during diagnosis and treatment of CS is not well characterized. In this review, we will discuss how cortisol is measured in clinical practice and the potential benefit of measurement and normalization of the cortisol circadian rhythm.
Overview
CoChat Summary
## TL;DR
This review argues that Cushing syndrome is not just excess cortisol, but also a disorder of disrupted cortisol circadian rhythm, and that current single-time-point tests miss clinically important variability. It highlights emerging tools—especially multiple salivary measures, hair cortisol/cortisone, and continuous subcutaneous monitoring—as promising but not yet fully validated for routine use.
## Key findings
- Current standard screening tests for Cushing syndrome—24-hour urinary free cortisol (UFC), late-night salivary cortisol (LNSC), and the 1-mg dexamethasone suppression test (DST)—each have important limitations and can miss cyclical or mild disease because they sample cortisol at a single point or over a limited period.
- In the paper’s cited study of 12 patients with mild autonomous cortisol secretion (MACS) vs 10 referent subjects, 24-hour total/free cortisol levels were similar, but cortisol secretion differed significantly at 2200 and 0000 hours, showing that circadian disruption can exist despite normal integrated cortisol measures.
- Hair cortisol/cortisone studies report diagnostic cutoffs of about 5–31 pg/mg for hair cortisol and 14–28 pg/mg for hair cortisone, with sensitivities of approximately 60–100% and specificities of approximately 79–99%, but thresholds vary widely.
- Continuous subcutaneous cortisol monitoring has produced 72-hour profiles in 16 healthy men and 24-hour dynamic profiles in 214 healthy volunteers, but the devices are not yet approved for clinical use and remain research tools.
## Methods
- Narrative review of cortisol measurement in endogenous Cushing syndrome, covering diagnosis, monitoring, circadian rhythm assessment, and treatment response.
- Synthesizes evidence from screening-test guidance and multiple cited studies in patients with Cushing syndrome, MACS, and healthy controls, including studies using UFC, LNSC, DST, hair cortisol/cortisone, and continuous subcutaneous monitoring.
- Uses comparative interpretation of prior observational studies, prospective studies, phase 3 trial analyses, and case series to evaluate how well each cortisol measure reflects circadian rhythm and disease control.
## Limitations
- The paper itself states that the utility of assessing individual patients’ cortisol circadian rhythm during diagnosis and treatment is not well characterized, and that there is currently no guidance for monitoring treatment response with respect to restoration of cortisol circadian rhythm.
- It also states that continuous subcutaneous monitoring devices are not yet approved for clinical use, remain limited to research settings, and lack sufficient evidence for diagnostic purposes.
- Evident from the text: this is a review, so it does not present a single original patient cohort or one unified analytical dataset; conclusions depend on heterogeneous cited studies with varying assays, populations, and endpoints.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
38 Valid · 0 Not valid · 38 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These challenges often lead to delayed diagnosis, contributing to increased morbidity and mortality (48-50, 53).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Diagnostic algorithm
What the sources say
- Not checked — no full text of the sourcecites [48] Ceccato F, Bavaresco A, Ragazzi E, et al Clinical and biochemical data for the diagnosis of endogenous hypercortisolism: the “cushingomic” approach. J Clin Endocrinol Metab. 2025; 110(2): 396‐ 405. 39056252 source
- Supportedcites [49] Braun LT, Vogel F, Zopp S, et al Whom should we screen for Cushing syndrome? The Endocrine Society practice guideline recommendations 2008 revisited. J Clin Endocrinol Metab. 2022; 107(9): e3723‐ e3730. 35730067 PMC9387700 source
The Abstract (page not specified in the supplied passage) says that low incidence and overlapping symptoms can delay diagnosis and treatment, resulting in increased morbidity and mortality. The Implications for Clinical Practice section likewise links late diagnosis with increased morbidity and mortality. (LLM, conf=0.94)
- Partly supportedcites [50] Rubinstein G, Osswald A, Hoster E, et al Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab. 2020; 105(3): e12‐ e22. 31665382 sourceExperimental — accuracy not yet measured
The paper says that overlapping symptoms can delay CS diagnosis, and its Discussion reports a mean time to diagnosis of 34 months. It also says that the duration of hypercortisolism appears to be an important determinant of morbidity and premature mortality. However, it does not directly establish that the diagnostic delays it measured increased those outcomes; the claim presents that link more definitively than the paper does. (LLM, conf=0.82)
- Partly supportedcites [53] Ragnarsson O, Olsson DS, Papakokkinou E, et al Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study. J Clin Endocrinol Metab. 2019; 104(6): 2375‐ 2384. 30715394 sourceExperimental — accuracy not yet measured
Ragnarsson et al. (2019) clearly support the increased-morbidity/mortality half of the claim: the Abstract (Introduction) notes 50% of untreated CS patients died within 5 years of diagnosis and that mortality remains increased, particularly in patients not in remission, and the Conclusion (Discussion) states patients with CD continue to have excess mortality even after remission. However, the paper does not attribute this to diagnostic delay: the Discussion states that information on duration of active CS was not available, and that a related measure of untreated CS — time from diagnosis to curative treatment — was NOT associated with increased mortality risk (Cox model 1, HR 0.8, 95% CI 0.6–1.1, P = 0.16; Results, 'Influence of remission status...'). The only mention of duration of active disease as a mortality predictor is credited to a previous study (their reference 14), not to their own findings. Thus the causal link 'delayed diagnosis contributes to increased morbidity and mortality' is not what this source shows. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The loss of circadian rhythm with the absence of a late-night cortisol nadir is a hallmark biochemical abnormality in patients with CS (11, 25, 26).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Abstract
What the sources say
- Supportedcites [11] Nieman LK, Biller BMK, Findling JW, et al The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93(5): 1526‐ 1540. 18334580 PMC2386281 source
Section 3.4.2, ‘Evidence for late-night salivary cortisol,’ describes loss of circadian rhythm and absence of a late-night cortisol nadir as a consistent biochemical abnormality in patients with Cushing’s syndrome. ‘Hallmark’ is a fair paraphrase of that statement. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [25] Laidlaw JC, Reddy WJ, Jenkins D, Haydar NA, Renold AE, Thorn GW. Advances in the diagnosis of altered states of adrenocortical function. N Engl J Med. 1955; 253(18): 747‐ 753. 13266035 source
- Not checked — no full text of the sourcecites [26] Doe RP, Vennes JA, Flink EB. Diurnal variation of 17-hydroxycorticosteroids, sodium, potassium, magnesium and creatinine in normal subjects and in cases of treated adrenal insufficiency and Cushing's syndrome. J Clin Endocrinol Metab. 1960; 20(2): 253‐ 265. 13817162 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although overt physical features may be absent, the subtle hypercortisolism seen in MACS has been associated with adverse cardiovascular and metabolic outcomes, including hypertension, diabetes, dyslipidemia, weight gain, osteoporosis, increased frailty, and increased mortality (33, 34, 97-101).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Stratification of hypercortisolism
What the sources say
- Partly supportedcites [33] Li D, Zhang CD, Saini J, et al Determinants of muscle function and health-related quality of life in patients with endogenous hypercortisolism: a cross-sectional study. Eur J Endocrinol. 2023; 189(1): 40‐ 49. PMC10376436 37327378 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [34] Braun LT, Vogel F, Nowak E, et al Frequency of clinical signs in patients with Cushing's syndrome and mild autonomous cortisol secretion: overlap is common. Eur J Endocrinol. 2024; 191(4): 473‐ 479. 39351910 source
- Not checked — no full text of the sourcecites [97] Elhassan YS, Alahdab F, Prete A, et al Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019; 171(2): 107‐ 116. 31234202 source
- Partly supportedcites [98] Pelsma CM, Fassnacht M, Tsagarakis S, et al Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol. 2023; 189(4): S88‐ S101. 37801655 sourceExperimental — accuracy not yet measured
Pelsma et al. (2023) support most of the list: the Discussion (p. ~"Discussion") states that "the prevalence of cardiometabolic diseases was increased in patients with MACS, with the prevalence of diabetes, hypertension, and dyslipidemia being 15%-40% higher," with pooled RRs of 1.44 (diabetes), 1.24 (hypertension) and 1.23 (dyslipidemia) in the Metabolic and cardiovascular comorbidities section, and increased mortality (HR = 1.54, 95% CI 1.27-1.81) in the Mortality section; the Introduction also frames MACS as hypercortisolism without clinical signs of overt Cushing's syndrome. However, our copy contains no comorbidity outcome on weight gain/obesity or on frailty (searched: obesity, body mass index, weight gain, frailty, bone mineral density) — the only bone-related data are on vertebral/fragility fractures, where prevalence of multiple fracture types "was assessed and found to have not increased" and no pooled statistic was provided, so the osteoporosis element is at best weakly reflected. The claim also states these associations flatly, whereas the source hedges them (dyslipidemia "less solid," causality "disputed," quality of evidence low). (LLM, conf=0.78)
- Partly supportedcites [99] Dogra P, Šambula L, Saini J, et al High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment. Eur J Endocrinol. 2023; 189(3): 318‐ 326. 37590964 PMC10479159 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Could not verifycites [100] Prete A, Subramanian A, Bancos I, et al Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: a cross-sectional multicenter study. Ann Intern Med. 2022; 175(3): 325‐ 334. 34978855 sourceExperimental — accuracy not yet measured
Our copy of Prete et al. (2022) contains only the repository metadata record — the title, full author list, journal details (Ann Intern Med 175(3):325-334), the RIS/BIBTEX citation blocks, an 'Abstract' heading with no abstract text, and a link to the manuscript PDF. No passage addresses mild autonomous cortisol secretion or any of the outcomes in the claim (hypertension, diabetes, dyslipidemia, weight gain, osteoporosis, frailty, mortality); searches with 'mild autonomous cortisol secretion cardiometabolic disease burden', 'subtle hypercortisolism adverse outcomes mortality frailty osteoporosis', 'abnormal dexamethasone suppression test', 'urinary steroid excretion ... abstract', and 'hypertension type 2 diabetes dyslipidemia obesity bone mineral density fracture mortality' returned only metadata. The decisive content is therefore absent from our copy rather than contradicted. (LLM, conf=0.72)
- Partly supportedcites [101] Deutschbein T, Reimondo G, Di Dalmazi G, et al Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabets Endocrinol. 2022; 10(7): 499‐ 508. PMC9679334 35533704 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The diagnosis of endogenous CS can be challenging due to overlap with common conditions, highly variable clinical features, and challenges in appropriately interpreting biochemical screening and diagnostic tests (11, 48-52).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Diagnostic algorithm
What the sources say
- Supportedcites [11] Nieman LK, Biller BMK, Findling JW, et al The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93(5): 1526‐ 1540. 18334580 PMC2386281 source
Section 1.0 says that Cushing’s syndrome has a broad clinical presentation, can be challenging to diagnose in mild cases, and overlaps with common conditions. Sections 3.4 and 3.6–3.8 describe variable hypercortisolism, discordant results, assay-dependent normal ranges, and the need to interpret tests in light of patient- and test-specific caveats. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [48] Ceccato F, Bavaresco A, Ragazzi E, et al Clinical and biochemical data for the diagnosis of endogenous hypercortisolism: the “cushingomic” approach. J Clin Endocrinol Metab. 2025; 110(2): 396‐ 405. 39056252 source
- Supportedcites [49] Braun LT, Vogel F, Zopp S, et al Whom should we screen for Cushing syndrome? The Endocrine Society practice guideline recommendations 2008 revisited. J Clin Endocrinol Metab. 2022; 107(9): e3723‐ e3730. 35730067 PMC9387700 source
The copy’s Abstract section says diagnosis is difficult because symptoms vary and overlap with common conditions and pseudo-Cushing states. Patients and Data Acquisition also describes using multiple biochemical tests and repeating samples when results might be false positive or false negative, supporting the point about interpreting tests. (LLM, conf=0.85)
- Partly supportedcites [50] Rubinstein G, Osswald A, Hoster E, et al Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab. 2020; 105(3): e12‐ e22. 31665382 sourceExperimental — accuracy not yet measured
The introduction says CS symptoms overlap with other conditions and can delay diagnosis. The Discussion describes unusual and progressive presentations and says current biochemical screening tests have significant sensitivity and specificity issues (p. 22). These passages support diagnostic difficulty, but do not specifically address challenges in interpreting screening or diagnostic test results. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [51] Klose MC, Lange M, Rasmussen AK, et al Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab. 2007; 92(4): 1326‐ 1333. 17244781 source
- Supportedcites [52] Giraldi FP, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007; 92(11): 4123‐ 4129. 17698908 source
The introduction (p. 1) says recognizing endogenous Cushing’s syndrome remains challenging because patients may have only subtle clinical features and clinicians must consider it in people with common conditions such as obesity, depression, hypertension, and diabetes. The Discussion (pp. 4, 6) describes the difficulty of choosing and interpreting screening tests and diagnostic thresholds. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among patients with CS, normalization of cortisol concentrations results in improvements in morbidity, mortality, and quality of life (28, 35, 109, 110).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Stratification of hypercortisolism
What the sources say
- Not checked — no full text of the sourcecites [28] Puglisi S, Perini AME, Botto C, Oliva F, Terzolo M. Long-term consequences of Cushing syndrome: a systematic literature review. J Clin Endocrinol Metab. 2024; 109(3): e901‐ e919. 37536275 source
- Partly supportedcites [35] Schernthaner-Reiter MH, Siess C, Gessl A, et al Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission. Endocrine. 2019; 64(1): 157‐ 168. 30467627 PMC6453862 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says remission of glucocorticoid excess often improves signs and symptoms, but comorbidities are not always reversible. The Discussion (page unavailable) notes residual impairment in quality of life, while the Introduction says cardiovascular mortality risk remains elevated decades after remission. The paper therefore does not support an unqualified claim of improvements in all three outcomes, particularly mortality. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [109] Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006; 91(2): 447‐ 453. 16278266 source
- Partly supportedcites [110] Newell-Price J, Fleseriu M, Pivonello R, et al Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol. J Endocr Soc. 2025; 9(1): bvae201. PMC11604051 39610378 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says cortisol normalization is a treatment goal intended to reduce comorbidities and mortality risk. The Results report improved cardiovascular/metabolic measures and quality of life in patients with Cushing disease whose cortisol measures were controlled. The paper does not report improved mortality, and describes mortality reduction as a potential benefit rather than an observed outcome. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
54 more claims · 18 with their cited sources checked
Create a free account to see all 96 claims and to verify the 24 references still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 8
- The quote only partly states this claim. 2
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
Adverse metabolic and cardiovascular consequences of circadian misalignment
Scheer, F. A. J. L., Hilton, M. F., Mantzoros, C. S., & Shea, S. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808180106 · Cited by 2,351
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk
Cohen, S., Janicki-Deverts, D., Doyle, W. J., Miller, G. E., Frank, E., Rabin, B. S., & Turner, R. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118355109 · Cited by 1,419
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects
WEITZMAN, E. D., FUKUSHIMA, D., NOGEIRE, C., ROFFWARG, H., GALLAGHER, T. F., & HELLMAN, L. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-1-14 · Cited by 1,258
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationFassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
Self-citationA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419
Valassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study
Ebbehoj, A., Li, D., Kaur, R. J., Zhang, C., Singh, S., Li, T., Atkinson, E., Achenbach, S., Khosla, S., Arlt, W., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30314-4 · Cited by 337
Self-citationvan Rossum, E. F. C., Koper, J. W., Huizenga, N. A. T. M., Uitterlinden, A. G., Janssen, J. A. M. J. L., Brinkmann, A. O., Grobbee, D. E., de Jong, F. H., van Duyn, C. M., Pols, H. A. P., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3128 · Cited by 329
Modified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322
ACTH Receptors in the Adrenal: Specific Binding of ACTH- 125 I and Its Relation to Adenyl Cyclase
Lefkowitz, R. J., Roth, J., Pricer, W., & Pastan, I. (1970) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.65.3.745 · Cited by 305
Ketoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285
The relationship between smoking status and cortisol secretion.
Badrick, E., Kirschbaum, C., & Kumari, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2155 · Cited by 284
High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278
Huizenga, N. A. T. M. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.1.144 · Cited by 265
Elhassan, Y. S., Alahdab, F., Prete, A., Delivanis, D. A., Khanna, A., Prokop, L., Murad, M. H., O'Reilly, M. W., Arlt, W., & Bancos, I. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3630 · Cited by 263
Self-citationDevelopment of cortisol circadian rhythm in infancy
de Weerth, C., Zijl, R. H., & Buitelaar, J. K. (2003) · Early Human Development · doi:10.1016/s0378-3782(03)00074-4 · Cited by 248
Daniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231
Evidence for a Precursor in Vasopressin Biosynthesis
SACHS, H., & TAKABATAKE, Y. (1964) · Endocrinology · doi:10.1210/endo-75-6-943 · Cited by 225
Pivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citationHair analysis provides a historical record of cortisol levels in Cushing's syndrome
Thomson, S., Koren, G., Fraser, L.-A., Rieder, M., Friedman, T. C., & Van Uum, S. H. M. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1220771 · Cited by 218
Lindsay, J. R., Nansel, T., Baid, S., Gumowski, J., & Nieman, L. K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1058 · Cited by 210
Deutschbein, T., Reimondo, G., Di Dalmazi, G., Bancos, I., Patrova, J., Vassiliadi, D. A., Nekić, A. B., Debono, M., Lardo, P., Ceccato, F., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00100-0 · Cited by 205
Self-citationCabergoline monotherapy in the long-term treatment of Cushing's disease
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0382 · Cited by 202
Self-citationMEIKLE, A. W. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb00733.x · Cited by 201
Late-night salivary cortisol as a screening test for cushing's syndrome
Raff, H. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.8.2681 · Cited by 194
Wood, P. J., Barth, J. H., Freedman, D. B., Perry, L., & Sheridan, B. (1997) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329703400302 · Cited by 190
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Mortality and morbidity in Cushing's syndrome in New Zealand
Bolland, M. J., Holdaway, I. M., Berkeley, J. E., Lim, S., Dransfield, W. J., Conaglen, J. V., Croxson, M. S., Gamble, G. D., Hunt, P. J., & Toomath, R. J. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04124.x · Cited by 182
Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients
Rubinstein, G., Osswald, A., Hoster, E., Losa, M., Elenkova, A., Zacharieva, S., Machado, M. C., Hanzu, F. A., Zopp, S., Ritzel, K., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz136 · Cited by 180
Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.
Liu, H., Bravata, D. M., Cabaccan, J., Raff, H., & Ryzen, E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02395.x · Cited by 178
PATTERNS OF ACTH AND CORTISOL PULSATILITY OVER TWENTY‐FOUR HOURS IN NORMAL MALES AND FEMALES
HORROCKS, P. M., JONES, A. F., RATCLIFFE, W. A., HOLDER, G., WHITE, A., HOLDER, R., RATCLIFFE, J. G., & LONDON, D. R. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb03758.x · Cited by 177
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Self-citationTHE NORMAL LEVELS OF 17-HYDROXYCORTICOSTEROIDS IN THE PERIPHERAL BLOOD OF MAN 1
Bliss, E. L., Sandberg, A. A., Nelson, D. H., & Eik-Nes, K. (1953) · Journal of Clinical Investigation · doi:10.1172/jci102798 · Cited by 168
The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome
Findling, J. W., Raff, H., & Aron, D. C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030207 · Cited by 165
van Rossum, E. F. C., Voorhoeve, P. G., te Velde, S. J., Koper, J. W., Delemarre-van de Waal, H. A., Kemper, H. C. G., & Lamberts, S. W. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031422 · Cited by 164
A Diurnal Rhythm in the Excretion of Urinary Ketosteroids by Young Men1
Pincus, G. (1943) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-3-4-195 · Cited by 156
Prete, A., Subramanian, A., Bancos, I., Chortis, V., Tsagarakis, S., Lang, K., Macech, M., Delivanis, D. A., Pupovac, I. D., Reimondo, G., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-1737 · Cited by 154
Self-citationOutcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years
Hassan-Smith, Z. K., Sherlock, M., Reulen, R. C., Arlt, W., Ayuk, J., Toogood, A. A., Cooper, M. S., Johnson, A. P., & Stewart, P. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2957 · Cited by 153
High variability in baseline urinary free cortisol values in patients with Cushing's disease
Petersenn, S., Newell‐Price, J., Findling, J. W., Gu, F., Maldonado, M., Sen, K., Salgado, L. R., Colao, A., Biller, B. M. K., & Pasireotide B2305 Study Group (2014) · Clinical Endocrinology · doi:10.1111/cen.12259 · Cited by 150
Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up
Ntali, G., Asimakopoulou, A., Siamatras, T., Komninos, J., Vassiliadi, D., Tzanela, M., Tsagarakis, S., Grossman, A. B., Wass, J. A. H., & Karavitaki, N. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0569 · Cited by 149
Klose, M., Lange, M., Rasmussen, A. K., Skakkebæk, N. E., Hilsted, L., Haug, E., Andersen, M., & Feldt-Rasmussen, U. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1791 · Cited by 140
Evidence for Two Subtypes of Cushing's Disease Based on the Analysis of Episodic Cortisol Secretion
Van Cauter, E., & Refetoff, S. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505233122102 · Cited by 137
DOE, R. P., VENNES, J. A., FLINK, E. B., ENGST, R., JOHNSON, P., & LEWIS, M. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-2-253 · Cited by 137
Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study
Ragnarsson, O., Olsson, D. S., Papakokkinou, E., Chantzichristos, D., Dahlqvist, P., Segerstedt, E., Olsson, T., Petersson, M., Berinder, K., Bensing, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02524 · Cited by 134
Qureshi, A. C., Bahri, A., Breen, L. A., Barnes, S. C., Powrie, J. K., Thomas, S. M., & Carroll, P. V. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02784.x · Cited by 133
Nychthemeral Variations in Plasma Free Corticosteroid Levels of the Rat.
Guillemin, R., Dear, W. E., & Liebelt, R. A. (1959) · Experimental Biology and Medicine · doi:10.3181/00379727-101-24955 · Cited by 130
Pelsma, I. C. M., Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad134 · Cited by 130
Self-citationKidambi, S., Raff, H., & Findling, J. W. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0424 · Cited by 129
Debono, M., Harrison, R. F., Whitaker, M. J., Eckland, D., Arlt, W., Keevil, B. G., & Ross, R. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3694 · Cited by 128
Manenschijn, L., Koper, J. W., van den Akker, E. L. T., de Heide, L. J. M., Geerdink, E. A. M., de Jong, F. H., Feelders, R. A., & van Rossum, E. F. C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1852 · Cited by 122
Pecori Giraldi, F., Ambrogio, A. G., De Martin, M., Fatti, L. M., Scacchi, M., & Cavagnini, F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0596 · Cited by 121
Randomized trial of osilodrostat for the treatment of Cushing disease
Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac178 · Cited by 114
Probability theory in the diagnosis of Cushing's syndrome.
NUGENT, C. A., WARNER, H. R., DUNN, J. T., & TYLER, F. H. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-7-621 · Cited by 112
High fluid intake increases urine free cortisol excretion in normal subjects.
Mericq, M. V., & Cutler, G. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4555 · Cited by 111
van Haalen, F. M., Broersen, L. H. A., Jorgensen, J. O., Pereira, A. M., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0556 · Cited by 103
Fleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30313-4 · Cited by 101
Accuracy of laboratory tests for the diagnosis of Cushing syndrome
Galm, B. P., Qiao, N., Klibanski, A., Biller, B. M. K., & Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa105 · Cited by 100
Debono, M., Harrison, R. F., Chadarevian, R., Gueroult, C., Abitbol, J.-L., & Newell-Price, J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00823 · Cited by 100
Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests
Alwani, R. A., Schmit Jongbloed, L. W., de Jong, F. H., van der Lely, A. J., de Herder, W. W., & Feelders, R. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0702 · Cited by 98
Ueland, G. Å., Methlie, P., Kellmann, R., Bjørgaas, M., Åsvold, B. O., Thorstensen, K., Kelp, O., Thordarson, H. B., Mellgren, G., Løvås, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0078 · Cited by 94
High-resolution daily profiles of tissue adrenal steroids by portable automated collection
Upton, T. J., Zavala, E., Methlie, P., Kämpe, O., Tsagarakis, S., Øksnes, M., Bensing, S., Vassiliadi, D. A., Grytaas, M. A., Botusan, I. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8464 · Cited by 94
Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center
Yaneva, M., Kalinov, K., & Zacharieva, S. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0320 · Cited by 93
Cortisol Measures Across the Weight Spectrum
Schorr, M., Lawson, E. A., Dichtel, L. E., Klibanski, A., & Miller, K. K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2078 · Cited by 92
Approach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91
Nieman, L. K., Castinetti, F., Newell-Price, J. D. C., Valassi, E., Drouin, J., Takahashi, Y., & Lacroix, A. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00588-w · Cited by 90
Self-citationAssociation of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant
Lin, R. C. Y., Wang, X. L., Dalziel, B., Caterson, I. D., & Morris, B. J. (2003) · Obesity Research · doi:10.1038/oby.2003.111 · Cited by 83
Advances in the diagnosis of altered states of adrenocortical function
Laidlaw, J. C., Reddy, W. J., Jenkins, D., Haydar, N. A., Renold, A. E., & Thorn, G. W. (1955) · New England Journal of Medicine · doi:10.1056/nejm195511032531801 · Cited by 82
Hurtado, M. D., Cortes, T., Natt, N., Young, W. F., & Bancos, I. (2018) · Clinical Endocrinology · doi:10.1111/cen.13803 · Cited by 76
Self-citationLongitudinal Change in Cortisol Levels Across the Adult Life Span
Moffat, S. D., An, Y., Resnick, S. M., Diamond, M. P., & Ferrucci, L. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gly279 · Cited by 72
Circadian Cortisol Secretory Rhythms in Cushing's Disease*
BOYAR, R. M., WITKIN, M., CARRUTH, A., & RAMSEY, J. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-48-5-760 · Cited by 72
Hypercortisolism and the Resistance to Dexamethasone Suppression during Gestation.
ODAGIRI, E., ISHIWATARI, N., ABE, Y., JIBIKI, K., ADACHI, T., DEMURA, R., DEMURA, H., & SHIZUME, K. (1988) · Endocrinologia Japonica · doi:10.1507/endocrj1954.35.685 · Cited by 70
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Faggiano, A., Bodei, L., de Krijger, R. R., Lombardi, G., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0728 · Cited by 68
Hiroshige, T., & Sakakura, M. (1971) · Neuroendocrinology · doi:10.1159/000121952 · Cited by 67
Effect of night-shift work on cortisol circadian rhythm and melatonin levels
Brum, M. C. B., Senger, M. B., Schnorr, C. C., Ehlert, L. R., & Rodrigues, T. D. C. (2022) · Sleep Science · doi:10.5935/1984-0063.20220034 · Cited by 66
Continuous free cortisol profiles-circadian rhythms in healthy men
Bhake, R. C., Kluckner, V, Stassen, H., Russell, G. M., Leendertz, J., Stevens, K., Linthorst, A. C. E., & Lightman, S. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00449 · Cited by 64
Giuffrida, G., Crisafulli, S., Ferraù, F., Fontana, A., Alessi, Y., Calapai, F., Ragonese, M., Luxi, N., Cannavò, S., & Trifirò, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01754-1 · Cited by 61
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
Newell-Price, J., Pivonello, R., Tabarin, A., Fleseriu, M., Witek, P., Gadelha, M. R., Petersenn, S., Tauchmanova, L., Ravichandran, S., Gupta, P., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0695 · Cited by 60
Self-citationFactors predicting long-term comorbidities in patients with Cushing's syndrome in remission
Schernthaner-Reiter, M. H., Siess, C., Gessl, A., Scheuba, C., Wolfsberger, S., Riss, P., Knosp, E., Luger, A., & Vila, G. (2019) · Endocrine · doi:10.1007/s12020-018-1819-6 · Cited by 60
Circadian rhythm of serum cortisol in Cushing's disease.
GLASS, A. R., ZAVADIL, A. P., HALBERG, F., CORNELISSEN, G., & SCHAAF, M. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-1-161 · Cited by 59
Nickelsen, T., Lissner, W., & Schöffling, K. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1210910 · Cited by 55
Trementino, L., Appolloni, G., Concettoni, C., Cardinaletti, M., Boscaro, M., & Arnaldi, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0722 · Cited by 53
Long-term consequences of Cushing syndrome: a systematic literature review
Puglisi, S., Perini, A. M. E., Botto, C., Oliva, F., & Terzolo, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad453 · Cited by 53
Braun, L. T., Vogel, F., Zopp, S., Marchant Seiter, T., Rubinstein, G., Berr, C. M., Künzel, H., Beuschlein, F., & Reincke, M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac379 · Cited by 52
Acute and Life-threatening Complications in Cushing Syndrome: Prevalence, Predictors, and Mortality
Schernthaner-Reiter, M. H., Siess, C., Micko, A., Zauner, C., Wolfsberger, S., Scheuba, C., Riss, P., Knosp, E., Kautzky-Willer, A., Luger, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab058 · Cited by 50
Neural Control of the Pituitary Gland.—II
Harris, G. W. (1951) · BMJ · doi:10.1136/bmj.2.4732.627 · Cited by 48
REFETOFF, S., VAN CAUTER, E., FANG, V. S., LADERMAN, C., GRAYBEAL, M. L., & LANDAU, R. L. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-3-527 · Cited by 46
Tanaka, T., Satoh, F., Ujihara, M., Midorikawa, S., Kaneko, T., Takeda, T., Suzuki, A., Sato, M., & Shimatsu, A. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0617 · Cited by 44
Li, J., Bidlingmaier, M., Petru, R., Gil, F., Loerbroks, A., & Angerer, P. (2018) · Journal of occupational medicine and toxicology · doi:10.1186/s12995-018-0204-y · Cited by 42
Rosmond, R., & Holm, G. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00008.x · Cited by 41
Savas, M., Wester, V. L., de Rijke, Y. B., Rubinstein, G., Zopp, S., Dorst, K., van den Berg, S. A. A., Beuschlein, F., Feelders, R. A., Reincke, M., et al. (2019) · Neuroendocrinology · doi:10.1159/000498886 · Cited by 41
Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy.
Kyriazopoulou, V. E., & Vagenakis, A. G. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.1.1619024 · Cited by 40
Scalp hair cortisol for diagnosis of Cushing's syndrome
Wester, V. L., Reincke, M., Koper, J. W., van den Akker, E. L. T., Manenschijn, L., Berr, C. M., Fazel, J., de Rijke, Y. B., Feelders, R. A., & van Rossum, E. F. C. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0873 · Cited by 39
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease
van der Pas, R., de Bruin, C., Pereira, A. M., Romijn, J. A., Netea-Maier, R. T., Hermus, A. R., Zelissen, P. M., de Jong, F. H., van der Lely, A. J., de Herder, W. W., et al. (2013) · Pituitary · doi:10.1007/s11102-012-0452-2 · Cited by 39
Vogg, N., Kurlbaum, M., Deutschbein, T., Gräsl, B., Fassnacht, M., & Kroiss, M. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab056 · Cited by 38
Rosmalen, J. G. M., Kema, I. P., Wüst, S., van der Ley, C., Visser, S. T., Snieder, H., & Bakker, S. J. L. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.018 · Cited by 38
Dogra, P., Šambula, L., Saini, J., Thangamuthu, K., Athimulam, S., Delivanis, D. A., Baikousi, D. A., Nathani, R., Zhang, C. D., Genere, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad113 · Cited by 38
Self-citationKannankeril, J., Carroll, T., Findling, J. W., Javorsky, B., Gunsolus, I. L., Phillips, J., & Raff, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa107 · Cited by 36
Mondin, A., Barbot, M., Voltan, G., Tizianel, I., Vedolin, C. K., Mazzeo, P., Lazzara, M., Boscaro, M., Scaroni, C. M., & Ceccato, F. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02099-z · Cited by 31
Carafone, L. E., Zhang, C. D., Li, D., Lazik, N., Hamidi, O., Hurtado, M. D., Young, W. F., Thomas, M. A., Dy, B. M., Lyden, M. L., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070741 · Cited by 31
Self-citationDeutschbein, T., Broecker-Preuss, M., Hartmann, M., Althoff, R., Wudy, S., Mann, K., & Petersenn, S. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1286297 · Cited by 30
Hair cortisol and cortisone measurements for the diagnosis of overt and mild Cushing's syndrome
Brossaud, J., Charret, L., De Angeli, D., Haissaguerre, M., Ferriere, A., Puerto, M., Gatta-Cherifi, B., Corcuff, J.-B., & Tabarin, A. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1127 · Cited by 29
Zhang, C. D., Li, D., Singh, S., Suresh, M., Thangamuthu, K., Nathani, R., Achenbach, S. J., Atkinson, E. J., Van Gompel, J. J., Young, W. F., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad073 · Cited by 29
Self-citationHasenmajer, V., Sbardella, E., Sciarra, F., Simeoli, C., Pivonello, C., Ceccato, F., Pofi, R., Minnetti, M., Rizzo, F., Ferrari, D., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105462 · Cited by 29
Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf206 · Cited by 28
Harrison, R. F., Debono, M., Whitaker, M. J., Keevil, B. G., Newell-Price, J., & Ross, R. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01172 · Cited by 27
Serum steroid profiling in Cushing’s syndrome patients
Hána, V., Ježková, J., Kosák, M., Kršek, M., Hána, V., & Hill, M. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105410 · Cited by 27
Veldman, R. G. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4039 · Cited by 27
Roldán-Sarmiento, P., Lam-Chung, C. E., Hinojosa-Amaya, J. M., Morales-García, M., Guillén-Placencia, M. F., Pérez-Flores, G. E., León-Suárez, A., León-Domínguez, J., Balbuena-Álvarez, S., Nava de la Vega, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa774 · Cited by 25
Li, D., Zhang, C. D., Saini, J., Singh, S., Nathani, R., Thangamuthu, K., Suresh, M., Atkinson, E. J., Achenbach, S. J., Van Gompel, J., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad069 · Cited by 25
Self-citationDietary sodium intake and cortisol measurements
Chen, A. X., Haas, A. V., Williams, G. H., & Vaidya, A. (2020) · Clinical Endocrinology · doi:10.1111/cen.14262 · Cited by 23
Yoshida, K., Fukuoka, H., Odake, Y., Nakajima, S., Tachibana, M., Ito, J., Hosokawa, Y., Yamada, T., Miura, H., Suematsu, N., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00375 · Cited by 23
Characterization of cyclic Cushing's disease using late night salivary cortisol testing
Jahandideh, D., Swearingen, B., Nachtigall, L. B., Klibanski, A., Biller, B. M. K., & Tritos, N. A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13758 · Cited by 21
Newell-Price, J., Fleseriu, M., Pivonello, R., Feelders, R. A., Gadelha, M. R., Lacroix, A., Witek, P., Heaney, A. P., Piacentini, A., Pedroncelli, A. M., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae201 · Cited by 21
Self-citationSaini, J., Singh, S., Ebbehoj, A., Zhang, C. D., Nathani, R., Fell, V., Atkinson, E., Achenbach, S., Rivard, A., Singh, R., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae468 · Cited by 20
Self-citationSævik, Å. B., Wolff, A. B., Björnsdottir, S., Simunkova, K., Hynne, M. S., Dolan, D. W. P., Bratland, E., Knappskog, P. M., Methlie, P., Carlsen, S., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa202 · Cited by 19
Friedman, T. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-924281 · Cited by 19
Aberle, J., Wiesch, C. S. Z., Flitsch, J., Veigel, J., Schön, G., Jung, R., Reining, F., Lautenbach, A., Rotermund, R., & Riedel, N. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0870-8 · Cited by 18
Friedman, T. C., & Yanovski, J. A. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349791 · Cited by 18
Glucocorticoid receptor polymorphisms influence muscle strength in Cushing's syndrome
Müller, L. M., Kienitz, T., Deutschbein, T., Riester, A., Hahner, S., Burger-Stritt, S., Berr, C. M., Oßwald, A., Braun, L., Rubinstein, G., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz052 · Cited by 17
Braun, L. T., Vogel, F., Nowak, E., Rubinstein, G., Zopp, S., Ritzel, K., Beuschlein, F., & Reincke, M. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae127 · Cited by 15
Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy
Kyriazopoulou, V. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.1.315 · Cited by 14
Update on Medical Treatment of Cushing’s Syndrome
Dillon, B. R., Agrawal, N., Schwarz, Y., Dancel-Manning, K., Tabarin, A., Lacroix, A., Hofland, L. J., & Feelders, R. A. (2025) · Drugs · doi:10.1007/s40265-025-02223-8 · Cited by 13
Self-citationDoğanşen, S. Ç., Soyluk, Ö., Selek, A., Erol, S., Hekimsoy, Z., Esen, A. D., Dursun, H., Şahin, S., Örük, G., Mert, M., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1783-7901 · Cited by 12
Garg, R., Memon, S. S., Lila, A. R., Sarathi, V., Patil, P., Jamale, T., Bose, S., Karlekar, M. P., Patil, V. A., Shah, N. S., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae002 · Cited by 12
Imamovic, M., Bäcklund, N., Lundstedt, S., Brattsand, G., Aardal, E., Olsson, T., & Dahlqvist, P. (2023) · Endocrine Connections · doi:10.1530/ec-22-0324 · Cited by 12
Postoperative serum cortisol and Cushing disease recurrence in patients with corticotroph adenomas
Catalino, M. P., Moore, D. T., Ironside, N., Munoz, A. R., Coley, J., Jonas, R., Kearns, K., Min, L., Vance, M. L., Jane, J. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad347 · Cited by 11
Piasecka, M., Papakokkinou, E., Piasecki, A., Falhammar, H., & Ragnarsson, Ó. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf114 · Cited by 10
Giampietro, R. R., Cabral, M. V. G., Pereira, E. G., Machado, M. C., Vilar, L., & Nogueira, V. D. S. N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1332120 · Cited by 10
Diurnal salivary cortisol profiles in patients with Cushing's syndrome
Braun, L. T., Vogel, F., Zopp, S., Rubinstein, G., Schilbach, K., Künzel, H., Beuschlein, F., & Reincke, M. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1719-5381 · Cited by 8
Ceccato, F., Bavaresco, A., Ragazzi, E., Barbot, M., Boscaro, M., Basso, D., Scaroni, C., & Antonelli, G. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae517 · Cited by 7
Sharma, S. S., Saini, J., Chacko, S. R., Ahmadian, S., Fell, V. M., Erickson, D. Z., Peersen, A. F., Achenbach, S. J., Atkinson, E. J., & Bancos, I. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf553 · Cited by 7
Self-citationEffects of metyrapone in patients with mild hypercortisolism
Musolino, A., Favero, V., Parazzoli, C., Aresta, C., Testa, S., Persani, L., Corbetta, S., Chiodini, I., & Morelli, V. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf216 · Cited by 7
Kuzu, İ., Zuhur, S. S., Demir, N., Aktas, G., Öztürk, F. Y., & Altuntaş, Y. (2016) · Endokrynologia Polska · doi:10.5603/ep.a2016.0028 · Cited by 7
Lamback, E., Kasuki, L., Miranda, R. L., de Figueiredo, C. S., Wildemberg, L. E., & Gadelha, M. R. (2025) · Endocrine · doi:10.1007/s12020-025-04234-7 · Cited by 4
Wulkan, R. W., & van der Horst, M. (2021) · Biochemia Medica · doi:10.11613/bm.2021.010706 · Cited by 4
Lionetto, L., Bernardini, D. D., Costanzi, G., Maggio, R., Aloini, M. E., Roberto, G., Ricci, F., Biondo, I., Lardo, P., Salerno, G., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.04.035 · Cited by 3
Research works printed but not linked: 1
- Dallman MF, Yates FE. Dynamic asymmetries in the corticosteroid feedback path and distribution of tissue receptors. Am J Physiol. 1969; 216(5): 1221‐ 1230. 4309115
Cited by
Mild Autonomous ACTH Secretion: A Narrative Review of 52 Cases from the Literature
Nicoli, F., Eller-Vainicher, C., Cozzi, R. C., Chiodini, I., & Favero, V. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.016
Metadata
- Authors
- Hamidi, O., St-Jean, M., Lacroix, A., & Bancos, I.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Division of Endocrinology, Department of Medicine, Centre hospitalier de l’Université de Sherbrooke , Sherbrooke, QC J1H 5H3 ,
- Centre Hospitalier de l’Université de Montréal (CA)
- Mayo Clinic (US)
- Corresponding author
- Bancos, Irina
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2026-03-14
- Volume
- 111
- Issue
- 6
- Pages
- 1513-1527
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC13183435
- OpenAlex
- W7135403789
- Cited by
- 5
- References
- 136
- Citations by year
- 2026: 5
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- Recordati Rare Diseases Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, cortisol measurement, diurnal cortisol rhythm, hypercortisolism, biochemical tests
- MeSH terms
- Circadian Rhythm, Cushing Syndrome, Humans, Hydrocortisone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.